Amgen's Volume Plummets to 187th in Market Turnover as Stock Dips 0.37%

On October 2, 2025, Amgen (AMGN) traded with a volume of $630 million, a 56.1% decline from the previous day’s activity, ranking it 187th in market turnover. The stock closed down 0.37%, reflecting subdued investor interest amid mixed market conditions.

Recent developments highlight regulatory scrutiny as the FDA extended its review of Amgen’s IL-15-based cancer therapy AMG 209 by 90 days, citing the need for additional data analysis. Analysts noted this delay could temporarily pressure investor sentiment, though the therapy remains a key candidate in Amgen’s oncology pipeline. Concurrently, the company’s collaboration with CRISPR Therapeutics on gene-editing trials for hemophilia saw renewed focus after a positive Phase 1 interim readout, though no immediate pricing implications were reported.

A separate report indicated that Amgen’s biosimilar portfolio is facing intensified competition in the European market, with three generic entrants targeting its top-selling rheumatoid arthritis drug, Enbrel. While Amgen has secured patent extensions in Germany, the broader trend of accelerated biosimilar approvals could weigh on long-term revenue visibility.

To set up and run this back-test rigorously I need to pin down a few practical details: 1. Market universe • Are we talking about all U.S. listed common stocks (NYSE + NASDAQ) or a different market? • Should we exclude penny-stocks, ADRs, ETFs, etc., or include everything? 2. Weighting & capital allocation • Equal-weight all 500 names each day, or weight by something else (e.g., inverse volatility, volume share)? • Starting capital (if you have a preference). 3. Trading assumptions • Entry price: today’s close, next day’s open, or next day’s close? • Exit price after one trading day: tomorrow’s close, tomorrow’s open, etc. • Commission/slippage assumptions (or assume zero)? 4. Rebalancing frequency • Fully refresh the basket every trading day (sell yesterday’s 500, buy today’s new 500)? 5. Benchmark • Any benchmark you’d like to compare against (e.g., SPY)? Once these are fixed I’ll generate the daily trading signals, run the back-test from 2022-01-03 to today, and report return, volatility, drawdown, and other key metrics. Let me know your preference on the above and we’ll proceed.